3 Recent Moves by Benjamin Taylor’s Sophrosyne Capital

Benjamin J Taylor’s Sophrosyne Capital just reported three recent moves regarding Ventrus Biosciences Inc (NASDAQ:VTUS), MeetMe Inc (NYSEMKT:MEET), and Aspen Group Inc (OTCBB:ASPU).


Benjamin Taylor’s Sophrosyne Capital dumped its shares in Ventrus Biosciences Inc (NASDAQ:VTUS). The fund reported ownership of 0.22 million shares of the firm in the last reported quarter of 2013. The recent filing reveals that the fund sold its shares in the firm. Ventrus Biosciences Inc (NASDAQ:VTUS) currently trades at $3.93, and gained 4.5% so far in 2014. The firm insiders bought 15 thousand shares in 2013, and sold none.

Sophrosyne Capital also decreased its position in MeetMe Inc (NYSEMKT:MEET) by 0.3 million shares. The current position of the fund translates to a 5.7% ownership of the company. MeetMe Inc (NYSEMKT:MEET) currently trades at $2.23, and gained 21% so far in 2014. The firm had no insider purchases or sales in 2013.

Benjamin Taylor bought 6.04 million shares of Aspen Group Inc (OTCBB:ASPU), which represents 8.95% of the company. Aspen Group Inc (OTCBB:ASPU) shares currently trades at $0.159, and lost 11.6% so far in 2014. The firm insiders bought 35 thousand shares in 2013. On the other hand, no insider sale happened in 2013.

Sophrosyne Capital makes investments primarily in healthcare, technology, and services. The fund manages $151 million, and headquartered in New York, NY. Calix Inc (NYSE:CALX) represents the biggest position in the fund’s portfolio with a value of $12 million. $CALX currently trades at $8.23 and lost 12% so far in 2014. BioTelemetry, Inc. (NASDAQ:BEAT) represents the second big position the fund holds in its portfolio with a value of $10 million. $BEAT currently trades at $6.89, and lost 11.3% so far in 2014.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!